Overview

Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease

Status:
Recruiting

Trial end date:
2023-12-15

Target enrollment:

Participant gender:

Summary

This phase I trial evaluates the side effects of intraoperative photodynamic therapy with porfimer sodium in enhancing the response to immunotherapy with an immune checkpoint inhibitor drug in patients with non-small cell lung cancer with pleural disease. Photodynamic therapy is a technique that that works by combining a photosensitizing agent (porfimer sodium in this trial) and an intense light source to kill tumor cells. Photodynamic therapy may decrease the patients' symptoms and improve their quality of life.

Phase:

Phase 1

Details

Lead Sponsor:

Roswell Park Cancer Institute

Treatments:

Dihematoporphyrin Ether
Trioxsalen